OVERVIEW
Beleodaq is a histone deacetylase (HDAC) inhibitor which catalyzes the removal of acetyl groups from the lysine residues of histones and some non-histone proteins.\(^1\) *In vitro*, this results in the accumulation of acetylated histones and other proteins leading to cell cycle arrest and/or apoptosis in some transformed cells. Beleodaq exhibits preferential cytotoxicity towards tumor cells vs. normal cells.

Beleodaq, a HDAC inhibitor, is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).\(^1\)

Guidelines

NCCN guidelines on Primary Cutaneous Lymphoma (version 2.2019 – December 17, 2018) recommend Beleodaq for systemic therapy of mycosis fungoides/Sezary syndrome and for primary cutaneous CD30+ T-cell lymphoproliferative disorders.\(^3,4\)

POLICY STATEMENT
Prior authorization is recommended for medical benefit coverage of Beleodaq. Approval is recommended for those who meet the Criteria and Dosing for the listed indication(s). Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below.

Because of the specialized skills required for evaluation and diagnosis of patients treated with Beleodaq, as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Beleodaq to be prescribed by or in consultation with a physician who specializes in the condition being treated.

RECOMMENDED AUTHORIZATION CRITERIA
Coverage of Beleodaq is recommended in those who meet one of the following criteria:

FDA-Approved Indications
1. **T-Cell Lymphoma** (NOTE: Examples include Peripheral T-Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome, Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders, Adult T-Cell Leukemia/Lymphoma, Hepatosplenic Gamma-Delta T-Cell Lymphoma, Extranodal NK/T-Cell Lymphoma – Nasal Type).\(^2,4\) Approve for 1 year if Beleodaq is prescribed by or in consultation with an oncologist or a dermatologist.
**Dosing.** Approve the following dosing (A and B):

A) Each individual dose must not exceed 1,000 mg/m² given by intravenous infusion; AND

B) Beleodaq is administered once daily on Days 1 through 5 of each 21-day cycle.¹

---

**CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Beleodaq has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions.

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

---

**REFERENCES**


---

**HISTORY**

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual</td>
<td>Revised Peripheral T-Cell Lymphoma indication to T-Cell Lymphoma and rolled Peripheral T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome all under this indication. Added Hepatosplenic Gamma-Delta T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma – Nasal Type under this indication. Revised criteria for this indication to Beleodaq prescribed by or in consultation with an oncologist.</td>
<td>09/04/2019</td>
</tr>
</tbody>
</table>

09/04/2019